Extending our previous analyses to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we confirmed a drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified gp120-neutralizing epitopes. In contrast, the sensitivity to bNAbs targeting the gp41 membrane-proximal external region remained stable, suggesting a selective pressure on gp120 preferentially. Despite this evolution, selected combinations of bNAbs remain capable of neutralizing efficiently most of the circulating variants.
D
espite the ability of HIV-1 to evade the antibody response, some HIV-1-infected individuals develop high titers of broadly neutralizing antibodies (bNAbs) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Since 2009, thanks to the development of single-cell-based antibody cloning techniques, a large number of monoclonal bNAbs with outstanding potencies have been isolated from such individuals (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Most of them target a few major sites of vulnerability on HIV-1 Env. Three of these sites are located within the exterior glycoprotein gp120: the CD4-binding site (13, 18, (21) (22) (23) and two glycandependent epitopes involving the V1/V2 and the V3 loops (16, 19, 20, 24, 25) . A fourth site involves the membrane-proximal external region (MPER) of the transmembrane gp41 glycoprotein (15) . A few additional sites involve recently defined epitopes at the gp41-gp120 interface (14, 17, 26) . When passively transferred, these bNAbs can prevent either HIV-1 infection in humanized mice or simian-human immunodeficiency virus infection in macaques (27, 28) . In addition, these bNAbs can also suppress established infection in humanized mice and macaques (29) (30) (31) (32) . The data strongly support testing the efficacy of bNAbs in human clinical trials. In this context, it is important to define the sensitivity to neutralization of the most representative HIV-1 variants that must be targeted. Due to the genetic bottleneck that occurs at transmission, transmitted variants may possess a selective advantage, and therefore preventive immunoprophylaxis should target early/transmitted variants. In addition, the rapid evolution of the HIV-1 species and its adaptation to its new host, the human population, suggests taking into account the most recently spreading variants, i.e., those that have been isolated at the time of primary infection during the recent years, as representative(s) of the contemporary epidemic.
Based on these hypotheses, we and others reported that HIV-1 appears to become more resistant to antibody neutralization over the course of the epidemic (33, 34) . In our previous study, we compared the neutralization sensitivity of early/transmitted HIV-1 variants from patients infected by subtype B viruses at three periods of the epidemic (1987 to 1991, 1996 to 2000, and 2006 to 2010). A progressively increasing resistance to neutralization was observed over calendar time, for both human sera and the bNAbs b12, VRC01, VRC03, NIH45-46 G54W , PG9, PG16, PGT121, PGT128, and PGT145 (33) . Since then, bNAbs with increased potency or targeting different epitopes have been generated, including bNAbs improved by structure-based gene modifications (37) (38) (39) (40) (41) . Therefore, we extended the analyses to a panel of new bNAbs described: PG9-iMab, PG16-iMab, 10E8, 3BNC117, NIH45-46m2, NIH45-46m7, 10-1074, JM4sdAb, 8ANC195, and PG9-16-RSH (Table 1 ). This new study provides an updated overview of the potency and breadth of these bNAbs against early/ transmitted contemporary HIV-1 variants that could guide the selection of antibodies to be used in immunoprophylaxis strategies and of epitopes to be considered for vaccine design.
Increasing resistance to bNAbs targeting gp120. The HIV-1 population that we studied was described previously (33 [CP] ). For each patient, blood samples were collected shortly after infection (before 3 months postin-fection, except for a few cases). Pseudotyped viruses expressing envelope glycoprotein (Env) variants representative of the viral quasispecies infecting each patient were generated from the entire env gene amplified by reverse transcription-PCR from plasmaextracted viral RNA. Phylogenetic analysis of the env sequences of these viruses with a large series of env sequences issued from clade B variants isolated at the time of primary infection from patients of various geographic origins indicated that our viral population did not belong to a genetically restricted subset of viruses but could be considered representative of the entire clade B HIV-1 population worldwide (33) . In addition, the genetic diversity among the env sequences of our viral population increased gradually from HP to CP, suggesting that it mirrors the global genetic evolution of HIV-1 over the course of the epidemic (33) .
The neutralizing activities of bNAbs described in Table 1 were evaluated by using a luciferase reporter gene assay in TZM-bl cells based on single-round infection of Env-pseudotyped viruses (33) . Although the recent bNAbs that target the CD4-binding site, NIH45-46m2, NIH45-46m7 (both derived from NIH45-46 G54W ), and 3BNC117 were more potent than the previously tested b12, VRC01, VRC03, and NIH45-46 G54W , we observed still a significant decrease in sensitivity to neutralization over the three periods of the epidemic for all these bNAbs (Fig. 1A) . The median 50% inhibitory concentration (IC 50 ) of NIH45-46m2 increased progressively and significantly from 0.029 g/ml for HP to 0.098 g/ml for CP (P ϭ 0.012). For NIH45-46m7 and 3BNC117, the median IC 50 increased, respectively, from 0.035 and 0.020 g/ml for HP to 0.098 and 0.270 g/ml for IP and remained stable for CP (0.087 g/ml and 0.175 g/ml, respectively; P ϭ 0.013 and 0.017, respectively).
The modified bNAbs that target the N160-glycan V1V2 epitopes PG9-16-RSH, PG9-iMab, and PG16-iMab were also more potent than the previously tested PG9, PG16, and PGT145 to neutralize the early/transmitted viruses (Fig. 1B) . However, we still observed a significant decrease in sensitivity to neutralization over the three periods of the epidemic. The median IC 50 s of PG9-16-RSH, PG9-iMab, and PG16-iMab increased progressively from 0.160, 0.043, and 0.011 g/ml for HP to 2.495, 0.068, and 0.065 g/ml for CP, respectively. This trend was significant for PG9-16-RSH (P ϭ 0.012) and PG16-iMab (P ϭ 0.006) and just above the limit of significance for PG9-iMAb (P ϭ 0.084). PG9-iMab and PG16-iMab are bispecific antibodies that were constructed using the humanized anti-CD4 antibody ibalizumab (iMab) as the scaffold, onto which the antigen-binding domains of PG9 and PG16 were engrafted (40) . Interestingly, the sensitivity to the parental iMab was similar for HP, IP, and CP (median IC 50 s of 1.42, 1.47, and 1.35 g/ml, respectively; P ϭ 0.564) (Fig. 1B) , suggesting that the increasing resistance to PG9-iMAb and PG16-iMAb over the course of the epidemic was specifically due to the paratope domain of PG9 and PG16.
The potency of the bNAb 10-1074, isolated from the B-cell lineage encoding PGT121 targeting an N332-glycan V3 epitope (16) , was somewhat similar to that of the previous bNAbs PGT121 and PGT128. Although we also observed a trend for a decreasing sensitivity to neutralization by these reagents over the three periods, the phenomenon reached significance only for PGT128 (Fig.  1C ). These slight differences could be attributed to modalities of glycan recognition by these antibodies (16, 20) .
As previously reported (33) , the sensitivity to neutralization by 2G12 was low, even for viruses from HP, and no trend of increasing resistance to this bNAb was observed (Fig. 1D) . The exceptional nature of this antibody (42) associated with its low potency might explain the absence of drift for its targeted epitope. HIV-1 variants from CP were more resistant to the llama-derived antibody JM4sdAb than the variants that were transmitted 2 decades earlier (median IC 50 s of 1.720, 1.930, and 3.065 g/ml for HP, IP, and CP, respectively; P ϭ 0.002). This bNAb reacts with a CD4-induced epitope, and this reaction involves elements of both the coreceptor-and CD4-binding sites (37, 39) . Although not significant, a similar trend was observed for the human bNAb 8ANC195, which targets a newly defined glycan-dependent epitope adjacent to the CD4-binding site and spanning gp120-gp41 interface (17) . The median IC 50 increased progressively from HP to CP (median IC 50 s, 0.420, 0.980, and 3.020 g/ml for HP, IP, and CP, respectively; P ϭ 0.068) (Fig. 1D ). Future works with other bNAbs belonging to this class should provide additional information on the drift of this antigenic site which involves both envelope subunits, gp120 and gp41, and on the selective pressure that it undergoes.
The more recent bNAb 10E8 that targets the MPER was more potent than the previously tested MPER bNAbs 2F5 and 4E10. However, in agreement with our previous observations obtained with 2F5 and 4E10, no trend of increased resistance to 10E8 over time was observed (median IC 50 s, 0.195, 0.300, and 0.190 g/ml for HP, IP, and CP, respectively; P ϭ 0.416) (Fig. 1E) .
Altogether, these results fully confirmed our first observations that indicated an increasing resistance of HIV-1 clade B to bNAbs targeting the major gp120 epitopes over 2 decades. Interestingly, drift was observed-not for a single major neutralization region of gp120, but for almost all the identified neutralization targets evaluated. This suggests a continuous selective pressure involving all epitopes, and therefore a drift of the entire gp120. In contrast, we observed a constant stable sensitivity to bNAbs targeting the gp41 MPER, suggesting either a lack of selective pressure, a weak tolerance to mutations in this region, or a combination of both. The first possibility, lack of selective pressure, is supported by the low reported frequency of NAbs elicited to this region (4). Although anti-MPER antibodies have been detected in HIV-1-infected individuals, they are associated with the neutralizing activity of sera only in rare cases (4, 5, 43, 44) . The second possibility is supported by the fact that it is difficult to select resistant strains in vitro without impairing infectivity (45) . However, exceptional 4E10-resistant HIV-1 isolates with rare MPER polymorphisms have been described (46) . The fact that mutations within the MPER did not occur during passive immunization of HIV-1-infected individuals with 2F5 and 4E10 could be a result of both mechanisms (45) . Neutralization potency and breadth of bNAbs against early/ transmitted HIV-1 variants. The neutralizing activities of bNAbs against our panel of pseudotyped viruses were compared by using IC 50 heat map analysis ( Fig. 2A) . Only the bispecific antibodies PG9-iMab and PG16-iMab were able to neutralize all viruses at less than 1 g/ml. Their neutralization breadth was exceptional compared to that of the parental PG9 and PG16, or to PG9-16-RSH (a chimeric derivate of PG9 and PG16). PG9-iMab and PG16-iMab were also the most potent of all bNAbs tested, with geometric mean IC 50 s of 0.047 g/ml and 0.029 g/ml, respectively, which indicate 32-fold and 52-fold higher potency than iMab (1.51 g/ml) and 56-fold and 42-fold higher potency than PG9 (2.62 g/ml) and PG16 (1.22 g/ml), respectively (Fig. 2B) . The geometric mean IC 50 s of PG9-iMab, PG16-iMab, iMab, PG9, and PG16 observed with our panel of early/transmitted subtype B viruses were approximately 10-fold higher than those previously reported with a panel of viral isolates from all major circulating genetic subtypes derived from patients at various stages of infection (40) . These differences might be due to the fact that the virus populations were very different. Among all the other bNAbs, Comparisons are shown for the neutralization sensitivity of Env-pseudotyped viruses derived from historical patients (HP; n ϭ 11), intermediate patients (IP; n ϭ 15), and contemporary patients (CP; n ϭ 14) by the following groups of antibodies: b12, VRC01, VRC03, and NIH45-46 G54W (adapted from reference 33) and NIH45-46m2, NIH45-46m7, and 3BNC117 (this study) (A); PGT145, PG9, and PG16 (adapted from reference 33) and PG9-16-RSH, PG9-iMab, PG16-iMab, and iMab (this study) (B); PGT135, PGT121, and PGT128 (adapted from reference 33) and 10-1074 (this study) (C); 2G12 (adapted from reference 33) and 8ANC195 and JM4sdAb (this study) (D); 4E10 and 2F5 (adapted from reference 33) and 10E8 (this study) (D). Box plots show the distributions of antibody titers (IC 50 s) of each bNAb toward pseudotyped viruses of each period; the horizontal lines represent the 10th, median, and 90th percentiles. Each datum point represents the mean value of the assay performed in duplicate. Differences of neutralization sensitivity between viruses over calendar time were evaluated using a Jonckheere-Terpstra test. NIH45-46m2 and NIH45-46m7, which target the CD4-binding site, were the broadest and most potent. They neutralized 95% of viruses at less than 1 g/ml, with a geometric mean IC 50 s of 0.082 g/ml for NIH45-46m2 and 0.085 g/ml for NIH45-46-m7. The breadth and potency of 3BNC117 was only slightly lower, neutralizing 82.5% of viruses at less than 1 g/ml with a geometric mean IC 50 of 0.097 g/ml. The bNAb 10-1074 was the broadest and most potent antibody among those targeting the N332-glycan V3 region. It neutralized 80% of the viruses at less than 1 g/ml, with a geometric mean IC 50 of 0.106 g/ml, whereas PGT121 and PGT128 neutralized 70% and 67.5% of the viruses with geometric mean IC 50 s of 0.144 g/ml and 0.163 g/ml, respectively. Among antibodies that do not target the three major epitopes on gp120, 8ANC195 was the broadest and most potent. It neutralized 52.5% of viruses with a geometric mean IC 50 of 1.244 g/ml. (Fig. 2B) . The bNAb 10E8 was the most potent of the anti-MPER reagents, neutralizing 85% of the viruses at less than 1 g/ml with a geometric mean IC 50 of 0.216 g/ml (Fig. 2B) . Neutralization coverage of the most recently transmitted HIV-1 variants. The perspective of using some bNAbs in human clinical trials and as tools for vaccine design and the evolution of the HIV-1 species that we have described necessitate focusing our attention on early/transmitted viruses collected during the most recent years of the epidemic. We therefore analyzed the cumulative frequency of neutralization of the viruses from the CP according to IC 50 s of up to 1 g/ml, considering the area under the curve for each bNAb (Fig. 3A and B) . Besides the bispecific antibodies PG9-iMab and PG16-iMab, which showed exceptional neutralization coverage, the bNAbs NIH45-46m7, NIH45-46m2, 10-1074, 3BNC117, NIH45-46 G54W , and 10E8 were the most potent (Fig. 3B) . They neutralized between 71% and 86% of viruses at less than 1 g/ml (Fig. 3A) . It would be useful to identify a combination of bNAbs that would neutralize 100% of HIV-1 variants at a low concentration, in order to prevent escape of any variant resistant to 1 or 2 of the bNAbs. We therefore selected three of the most potent bNAbs identified above, each targeting a different epitope, and investigated the sensitivity of CP variants to neutralization by a 1:1:1 combination of NIH45-46m2, 10-1074, and 10E8. The observed neutralization coverage by various concentrations of this combination was compared to the theoretical coverage that would be obtained if the neutralizing activities were fully additive ( Fig.  3C and D) . The NIH45-46m2/10-1074/10E8 combination was able to neutralize all the contemporary HIV-1 variants with an IC 50 of Յ0.37 g/ml, reaching approximately the theoretical curve and the potency of the bispecific antibodies PG9-iMab (IC 50 , Յ0.22 g/ml) and PG16-iMab (IC 50 , Յ0.27 g/ml). The effect of this combination was nearly additive but neither synergistic nor antagonistic. Compared to the NIH45-46 G54W /PGT128 combination tested in our previous study, this new combination was more potent, reaching similar neutralization coverage at approximately 3-fold-lower bNAb concentrations (33) . These results suggest that optimal neutralization coverage of recently transmitted variants may be achieved by combining three bNAbs targeting different epitopes, i.e., the CD4-binding site, the N332-glycan-dependent V3 epitope, and the MPER.
In conclusion, the data confirm the ongoing adaptation of the HIV-1 species to the humoral immunity of the human population over the course of the epidemic, even using the most potent and broadly neutralizing monoclonal antibodies described to date. The drift in resistance to neutralization concerns only the external glycoprotein gp120, but not the MPER. It could suggest a high selective pressure on gp120, in agreement with the higher frequency of NAbs targeting the gp120 epitopes compared to the low frequency of NAbs to MPER in sera from elite neutralizers (4). Interestingly enough, almost all the identified major neutralization epitopes of gp120 are affected by this antigenic drift, suggesting that gp120 as a whole has progressively evolved in less than 3 decades. What mechanism has been responsible for this evolution? Has gp120 been shaped progressively by the neutralizing responses of the transmitters? It is difficult to privilege this hypothesis if we consider that most transmissions occur during acute infection, when bNAbs are not yet present in the transmitters, and that ancestral viruses are preferentially transmitted when transmissions occur during long-lasting infections (47, 48) . However, if it were the case, this would suggest that the evolution of sensitivity to neutralization has been driven by rare events of late transmission of isolates, selected under NAb pressure, that might have an advantage over ancestral viruses. In any case, it remains to be determined whether the antigenic drift has been associated with other functional modifications of gp120 properties, such as interactions with the receptor and coreceptors, or cell entry efficacy more globally. Such a functional drift could be associated with an increase or, alternatively, a decrease of HIV-1 virulence, a major question that must be addressed. Despite this evolution, the good news is that the most recently identified bNAbs, either modified as bispecific antibodies or associated in combinations selected to target different epitopes, still remain capable of efficiently neutralizing the most recently transmitted HIV-1 clade B variants. These bispecific antibodies or these documented combinations should be favored for human trials.
